Module 2 - Unlocking the Potential of HER2-Targeted Therapy
This module discusses the role of HER2 mutations in NSCLC, optimal testing methodologies to detect these alterations, appropriate utilization of HER2-targeted therapies in NSCLC, and strategies to optimize treatment with these agents.
Helena Yu, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY
Dr. Helena A. Yu is a Thoracic Oncologist and Associate Attending who focuses her clinical care and research on lung cancer at the Memorial Sloan Kettering Cancer Center, in New York, USA. She also holds a position as an Associate Professor of Medicine at Weill Cornell Medical College in New York.1.
Distinguish the clinical significance of HER2-related genomic alterations while selecting the optimal testing methodology for broad application in all patients with mNSCLC
2.
Integrate comprehensive and longitudinal treatment strategies that optimize dosing, pulmonary/cardiac safety, and distant metastases for patients receiving HER2-directed therapies in NSCLC
